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One of the impediments precluding long-term storage
of platelets for blood transfusion is that refrigerated
platelets are rapidly cleared from the circulation upon
transfusion. New evidence suggests that this clear-
ance is mediated in the liver by the Mac-1 integrin on
Kupffer cells recognizing clustered GPIb receptor on
platelets, leading to platelet phagocytosis. 
Platelets in the blood are the primary cells responsible
for the control of bleeding. Under normal circum-
stances, their activation in response to bleeding trig-
gers the clotting process; however, inappropriate
activation leads to thrombosis, the precipitating event
in heart disease and stroke. In contrast to other blood
components, platelets have a limited shelf-life for
transfusion purposes of 5 days, since they must be
stored at room temperature and are thus prone to
microbial contamination. This method of storage is
necessary because refrigeration of platelets, even for
short periods, leads to their rapid clearance from the
circulation upon transfusion. A recent study sheds
light on the mechanism underlying this phenomenon.
Interestingly Hoffmeister and colleagues [1] now
demonstrate that clusters of the glycoprotein (GP)Ib
alpha subunit of the platelet adhesion receptor GPIb-
IX-V are recognised by the Mac-1 integrin and this
interaction is responsible for the clearance of chilled
platelets upon transfusion. These findings suggest
that GPIb-targeted approaches might permit cold
platelet storage providing increased utility and sub-
stantial savings in healthcare cost. 
Although platelets normally circulate freely, they can
rapidly adhere to exposed breaks in the endothelium
and to activated endothelial cells. Such adherent
platelets are rapidly activated leading to platelet
aggregate formation through upregulation of the
platelet-specific integrin, GPIIb-IIIa and its subsequent
binding to adhesive ligands such as fibrinogen and
von Willebrand factor (vWF) [2,3]. vWF is also a key
protein mediating the initial platelet adhesion, via an
interaction with a unique multisubunit platelet adhe-
sion receptor, GPIb-IX-V. 
GPIb-IX-V consists of four type I membrane-span-
ning subunits, all of which are members of the leucine-
rich repeat protein superfamily. GPIbα is disulfide-
linked to GPIbβ, and these subunits are non-cova-
lently associated with GPIX and GPV in the ratio of
2:2:2:1 [2,3]. The extracellular amino-terminal domain
of GPIbα (282 residues) contains the primary ligand
recognition sequences and is separated from the
membrane by a sialomucin core. In resting platelets,
the cytoplasmic sequence of GPIbα (~100 residues)
provides a binding site for filamin A and filamin B. It is
thus the major membrane glycoprotein linked through
filamin to a network of short, submembranous actin fil-
aments [4,5]. The penultimate residue (Ser609) at the
carboxyl terminus of GPIbα is constitutively phospho-
rylated allowing binding of 14-3-3ζ and the assembly
of other signalling molecules such as phosphatidyli-
nositol 3-kinase and Src [2]. The cytoplasmic domain
of GPIbβ (~34 residues) contains an additional binding
site for 14-3-3ζ that requires protein kinase A (PKA)-
mediated phosphorylation at Ser166 and is adjacent
to an upstream positively charged motif that binds
calmodulin [6,7]. Calmodulin can also bind to the cyto-
plasmic tail of GPV [7].
The binding site for vWF is present in the amino-ter-
minal domain of GPIbα (residues 1–282). This consists
of an amino-terminal flanking sequence, eight leucine-
rich repeats, a carboxy-terminal flanking sequence
and an anionic sequence containing three sulfated
tyrosines (Figure 1). The interaction of GPIb-IX-V with
vWF is shear dependent and involves a specific
segment in vWF, the A1 domain. A-domains are found
in many adhesive proteins, including integrins such as
Mac-1, where they are present as an insert sequence
in the α-chain of the integrin. An insight into how
GPIbα and vWF interact has recently been provided
by the X-ray crystal structure of a gain-of-function A1
domain fragment of vWF in complex with a gain-of-
function fragment of the amino-terminal domain of
GPIbα (the gain-of-function mutation in each fragment
facilitates complex formation) [3,12,13]. Binding
involves contact of the A1 domain by residues in the
amino- and carboxy-terminal flanking sequences of
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Figure 1. The amino-terminal domain of GPIbα.
(A) Schematic representation of the amino-terminal domain of
GPIbα (residues 1–282) consisting of the leucine-rich repeats
(including the sequence 35–200) and their disulfide-looped
capping sequences. Sulfated tyrosine residues at 276, 278 and
279 are within an anionic sulfated sequence 269–282, defined
by the mocarhagin cleavage site at 282/283. Epitopes for five
anti-GPIbα monoclonal antibodies are indicated [8–10]. (B)
Function of anti-GPIbα antibodies in inhibiting GPIbα binding
to either von Willebrand factor (vWF) with ristocetin [8–10], or
to Mac-1 [11]. The glycopeptide antibiotic ristocetin activates
vWF to bind GPIbα in vitro and most accurately reflects the
shear-dependent interaction [10].
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GPIbα, as well as electrostatic interactions involving
the leucine-rich repeats (residues 60–128) [3,8,13].
Most notable is a major conformational change in the
carboxy-terminal flanking sequence, the β-switch,
allowing an extended β-sheet involving both receptor
and ligand [13].
GPIb-IX-V has additional roles in vascular biology.
The sulfated tyrosine sequence (Figure 1) provides a
binding site for α-thrombin that facilitates platelet acti-
vation through the thrombin receptors, PAR-1 and
PAR-4 [2]. GPIbα binds P-selectin, an interaction
involved in platelet translocation on activated endothe-
lium (Figure 2) [2,14]. Finally, Simon and coworkers
demonstrated that GPIbα was the primary recognition
site on platelets for the leukocyte integrin, Mac-1
(αMβ2; CD11b/CD18; CR3) [2,11], via an interaction
between the inserted A domain (I domain) of Mac-1
and the amino-terminal domain of GPIbα. Mac-1 is the
primary integrin present on monocytes/macrophages,
and is responsible for mediating phagocytic events. It
binds multiple ligands including the complement frag-
ment iC3b, and the cell adhesion molecule ICAM-1.
Interestingly, although the interaction of GPIbα with
both vWF and Mac-1 involves binding of homologous
A-domains, antibody-blocking experiments (Figure 1)
suggest the binding sites are in part distinct, with Mac-
1 recognition primarily involving the GPIbα carboxy-
terminal flanking sequence.
There is evidence to suggest that the interaction
between GPIbα and Mac-1 may provide a mechanism
for monocyte/macrophage transmigration through
thrombi during the response to injury in vascular repair
[15]. Hoffmeister et al. [1] have now described in Cell
an additional physiological role for this interaction,
namely in the clearance of cold-treated platelets. It has
long been recognized that exposure of platelets to
temperatures below 15oC leads to a change in shape
and this has been widely believed to be the cause of
their accelerated clearance. Both increased cytoplasmic
Ca2+ concentration and membrane phosphoinositide
clustering have been demonstrated to be causes for
cold-induced actin filament rearrangement and platelet
rounding [16,17]. Hoffmeister et al. [1] surprisingly
found that, although treatment of platelets with the
membrane-permeable Ca2+ chelator, EGTA-AM, and
the actin filament barbed-end capping agent, cytocha-
lasin B, kept them discoid on cooling [17], these
platelets were still rapidly cleared [1].
If platelet shape is therefore not critical for cold-
induced clearance, how is it occurring? Hoffmeister et
al. [1] made the key observation that cold-treated
mouse platelets are cleared in the liver by Kupffer cells
(sinusoidal macrophages), but that this did not occur in
Mac-1-deficient mice where the platelets were cleared
at the same rate as platelets held at room temperature.
The integrin Mac-1 is thus critical for the clearance of
cold-treated platelets, inferring a potential role for
GPIbα as the key element on platelets involved in this
phenomenon. Indeed, proteolytic removal of GPIbα
from mouse platelets prevented their clearance follow-
ing cold treatment. Similarly, selective removal of
GPIbα on cold-exposed human platelets by a snake
venom metalloproteinase, mocarhagin [18], prevented
their Mac-1-dependent phagocytosis by activated THP-
1 cells [1]. Some irreversible change clearly must occur
in GPIbα at low temperatures allowing its increased
recognition by Mac-1. Hoffmeister et al. [1] found that
chilling led to irreversible clustering of GPIbα on mouse
platelets as revealed by immunogold localization,
although whether this is the direct cause for enhanced
Mac-1 binding remains to be established.
A remarkable finding from this study is that, even
though cold-treated platelets are rapidly cleared, they
are inherently hemostatically effective [1]. For example,
cold treatment does not affect the capacity of GPIbα to
bind vWF, suggesting that the changes in GPIbα rec-
ognized by Mac-1 are distinct from GPIbα recognition
of vWF. Cold treatment does not lead to surface
expression of the α-granule activation marker, P-
selectin, or upregulation of the function of the GPIIb-IIIa
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Figure 2. Interactions of platelet GPIb-IX-
V.
(A) Platelet adhesion is mediated by
receptors, GPIb-IX-V and GPVI, that bind
von Willebrand factor (vWF) or collagen.
GPIbα binds vWF in subendothelial matrix
or plasma, P-selectin on activated
platelets or endothelial cells, and leuko-
cyte Mac-1. GPV and GPVI interact with
collagen. All these interactions may acti-
vate platelets, leading to aggregation
mediated by the integrin GPIIb-IIIa. (B) At
lower temperatures, clustering of GPIbα is
implicated in clearance of platelets from
the blood by a mechanism involving
hepatic macrophage Mac-1 [1]. The tem-
perature effects on surface topography of
other platelet receptors such as GPVI are
unknown.
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integrin. Circulating chilled platelets have normal hemo-
static function in Mac-1-deficient mice, and form
platelet aggregates at a wound site to a similar extent
as endogenous platelets.
These combined findings raise the intriguing possi-
bility that GPIbα could be modified in such a way that
cold platelet storage may be feasible with normal
hemostatic effectiveness and without accelerated
clearance. The obvious approach would be to prevent
the GPIbα clustering and/or conformational changes
that occur on cooling platelets, but this will require
additional molecular understanding of these phenom-
ena. One outstanding issue is how clustering of GPIbα
occurs at low temperature. Since clustering still
occurs in the presence of Ca2+ chelation and cytocha-
lasin B [1], mechanisms other than actin filament
rearrangement must be involved. 14-3-3ζ is dimeric
suggesting it could be involved in a receptor multi-
merization process; studies have shown that deletion
of the carboxy-terminal 14-3-3ζ binding site from
GPIbα markedly increases receptor motility [19].
Calmodulin is known to dissociate from GPIb-IX-V on
platelet activation [7], and this event could trigger
receptor aggregation. A third possibility is that recep-
tor clustering may involve only a subpopulation of
GPIb-IX-V. In this regard, Shrimpton et al. [20] have
reported a subpopulation of GPIb-IX-V receptors in
cholesterol-rich membrane rafts. There is also the
intriguing possibility that there may be an irreversible
conformational change in the carboxy-terminal flank-
ing sequence of GPIbα. This region is directly impli-
cated in Mac-1 binding [11], and is capable of
undergoing dramatic changes in conformation [13].
Finally, why have we developed a clearance mecha-
nism that only appears to operate for cold-activated
platelets? Hoffmeister et al. [1] speculate that since
platelets show increased responsiveness to activation
as the temperature falls below 37oC, they may act as
thermosensors ‘designed to be less responsive to
thrombogenic stimuli at the core body temperature of
the central circulation where coronary or cerebral
thrombosis could be lethal, but become primed for
activation at the lower temperatures of external body
surfaces, sites most susceptible to bleeding throughout
evolutionary history’. Consistent with this speculation,
they show that normal mice but not Mac-1-deficient
mice have decreased platelet counts after 2 hours of
exposure to 4oC, relative to the corresponding mice at
room temperature. Clearance of platelets by liver
Kupffer cells may thus provide a physiological mecha-
nism for removal of more activated platelets primed by
repeated exposure to lower temperature in the periph-
eral circulation.
References
1. Hoffmeister, K.M., Felbinger, T.W., Falet, H., Denis, C.V., Bergmeier,
W., Mayadas, T.N., von Andrian, U.H., Wagner, D.D., Stossel, T.P.
and Hartwig, J.H. (2003). The clearance mechanism of chilled blood
platelets. Cell 112, 87–97.
2. Berndt, M.C., Shen, Y., Dopheide, S.M., Gardiner, E.E. and
Andrews, R.K. (2001). The vascular biology of the GPIb-IX-V
complex. Thromb. Haemost. 86, 178–188.
3. Andrews, R.K., Gardiner, E.E., Shen, Y., Whisstock, J.C. and Berndt,
M.C. (2003). Molecules in focus: Glycoprotein Ib-IX-V. Int. J.
Biochem. Cell Biol., in press. 
4. Hartwig, J. and DeSisto, M. (1991). The cytoskeleton of the resting
human blood platelet: structure of the membrane skeleton and its
attachment to actin filaments. J. Cell Biol. 112, 407–425.
5. Fox, J.E.B. (2001). Cytoskeletal proteins and platelet signalling.
Thromb. Haemost. 86, 198–213.
6. Gu, M., Xi, X., Englund, G.D., Berndt, M.C. and Du, X. (1999). Analy-
sis of the roles of 14-3-3 in the platelet GPIb-IX-mediated activation
of integrin αIIbβ3 using a reconstituted mammalian cell expression
model. J. Cell Biol. 147, 1085–1096.
7. Andrews, R.K., Munday, A.D., Mitchell, C.A. and Berndt, M.C.
(2001). Interaction of calmodulin with the cytoplasmic domain of the
platelet membrane glycoprotein Ib-IX-V complex. Blood 98,
681–687.
8. Shen, Y., Romo, G.M., Dong, J.-F., Schade, A., McIntire, L.V.,
Kenny, D., Whisstock, J.C., Berndt, M.C., López, J.A. and Andrews,
R.K. (2000). Requirement of leucine-rich repeats of GP Ibα for
shear-dependent and static binding of von Willebrand factor to the
platelet membrane GPIb-IX-V complex. Blood 95, 903–910.
9. Shen, Y., Dong, J.-F., Romo, G.M., Arceneaux, W., Aprico, A., Gar-
diner, E.E., López, J.A., Berndt, M.C. and Andrews, R.K. (2002).
Functional analysis of the C-terminal flanking sequence of platelet
glycoprotein Ib alpha using canine-human chimeras. Blood 99,
145–150.
10. Dong, J.-F., Berndt, M.C., Schade, A., McIntire, L.V. Andrews, R.K.
and López JA. (2001). Ristocetin-dependent, but not botrocetin-
dependent, binding of von Willebrand factor to the platelet glyco-
protein Ib-IX-V complex correlates with shear-dependent
interactions. Blood 97, 162–168.
11. Simon, D.I., Chen, Z., Xu, H., Li, C.Q., Dong, J.-F., McIntire, L.V.,
Ballantyne, C.M., Zhang, L., Furman, M.I., Berndt, M.C. et al. (2000).
Platelet glycoprotein Ibα is a counterreceptor for the leukocyte inte-
grin Mac-1 (CD11b/CD18). J. Exp. Med. 192, 193–204.
12. Uff, S., Clemetson, J.M., Harrison, T., Clemetson, K.J. and Emsley,
J. (2002). Crystal structure of the platelet GPIbα N-terminal domain
reveals an unmasking mechanism for receptor activation. J. Biol.
Chem. 277, 35657–35663.
13. Huizinga, E.G., Tsuji, S., Romijn, R.A.P., Schiphorst, M.E., de Groot,
P.G., Sixma, J.J. and Gros, P. (2002). Structures of GPIbα and its
complex with the vWF A1-domain. Science 297, 1176–1179.
14. Romo, G.M., Dong, J.-F., Schade, A.J., Gardiner, E.E., Kansas, G.S.,
Li, C.Q., McIntire, L.V., Berndt, M.C. and López, J.A. (1999). The gly-
coprotein Ib-IX-V complex is a platelet counterreceptor for P-
selectin. J. Exp. Med. 190, 803–814.
15. Simon, D.I., Dhen, Z., Seifert, P., Edelman, E.R., Ballantyne, C.M.
and Rogers, C. (2000). Decreased neointimal formation in Mac-
1(–/–) mice reveals a role for inflammation in vascular repair after
angioplasty. J. Clin. Invest. 105, 293–300.
16. Winokur, R. and Hartwig, J.H. (1995). Mechanism of shape change
in chilled human platelets. Blood 85, 1796–1804.
17. Hoffmeister, K.M., Falet, H., Toker, A., Barkalow, K.L., Stossel, T.P.
and Hartwig, J.H. (2001). Mechanisms of cold-induced platelet actin
assembly. J. Biol. Chem. 276, 24751–24759.
18. Ward, C.M., Andrews, R.K., Smith, A.I. and Berndt, M.C. (1996).
Mocarhagin, a novel cobra venom metalloproteinase, cleaves the
platelet von Willebrand factor receptor glycoprotein Ibα. Identifica-
tion of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of
glycoprotein Ibα as a binding site for von Willebrand factor and α-
thrombin. Biochemistry 35, 4929–4938.
19. Dong, J.-F., Li, C.Q., Sae-Tung, G., Hyun, W., Afshar-Kharghan, V.
and López, J.A. (1997). The cytoplasmic domain of glycoprotein
(GP) Ibα constrains the lateral diffusion of the GP Ib-IX complex and
modulates von Willebrand factor binding. Biochemistry 36,
12421–12427.
20. Shrimpton, C.N., Borthakur, G., Larrucea, S., Cruz, M.A., Dong, J.-
F. and López, J.A. (2002). Localization of the adhesion receptor gly-
coprotein Ib-IX-V complex to lipid rafts is required for platelet
adhesion and activation. J. Exp. Med. 196, 1057–1066.
